Identification of immunodominant regions and linear B cell epitopes of the gE envelope protein of varicella-zoster virus.

The envelope proteins of varicella-zoster virus (VZV) are highly immunogenic and one of the most abundant is glycoprotein E (gE). However, its immunodominant regions and epitopes have not been identified. In this study, using human sera from individuals with recent varicella or zoster infections, we have localized antigenic sequences of gE using recombinant hybrid Ty-virus-like particles (VLPs) carrying overlapping fragments of the gE protein. gE(1-134)-VLPs (particles carrying amino acids 1-134 of gE) and, to a lesser extent, gE(101-161)-VLPs were found to be the most antigenic when tested by Western blotting and ELISA. Other fragments of gE (spanning residues 161-623) showed weak or no antigenicity. Pepscan analysis of human sera on overlapping synthetic peptides representing residues 1-135 of gE revealed that the most antigenic region was between residues 50 and 135. Three immunodominant sequences (residues 86-105, 116-135, and, to a lesser extent, 56-75) were detected using sera from both varicella and zoster patients. All sera from varicella, but not zoster, patients reacted strongly with an epitope in peptide 66-85. Other epitopes were recognized weakly by some varicella or zoster sera. More sera need to be tested to assess the potential disease specificity of these epitopes. The neutralizing monoclonal antibody (MAb) IF-B9 reacted with residues 71-90; however, another neutralizing MAb, SG1A, which bound to both gE(1-134)-VLPs and gE(101-161)-VLPs did not bind to any peptide. The identification of immunodominant sequences of gE will help toward the development of a subunit VZV vaccine.

[1]  A. Arvin The T‐lymphocyte response to varicella zoster virus and its relevance to vaccine development , 1994 .

[2]  A. Arvin Cell-mediated immunity to varicella-zoster virus. , 1992, The Journal of infectious diseases.

[3]  W. Jackson,et al.  Receptor properties of two varicella-zoster virus glycoproteins, gpI and gpIV, homologous to herpes simplex virus gE and gI , 1992, Journal of virology.

[4]  J. Moore,et al.  Induction of high-titer neutralizing antibodies, using hybrid human immunodeficiency virus V3-Ty viruslike particles in a clinically relevant adjuvant , 1991, Journal of virology.

[5]  Raymond B. Heath,et al.  Antibody responses in recipients of varicella vaccine assayed by immunoblotting , 1990, Journal of medical virology.

[6]  C. Grose,et al.  Cellular and humoral immunity to varicella zoster virus glycoproteins in immune and susceptible human subjects. , 1989, The Journal of infectious diseases.

[7]  A. Kingsman,et al.  The expression of hybrid HIV:Ty virus-like particles in yeast , 1987, Nature.

[8]  A. Kingsman,et al.  The functions and relationships of Ty-VLP proteins in yeast reflect those of mammalian retroviral proteins , 1987, Cell.

[9]  A. Gershon,et al.  Live attenuated varicella vaccine use in immunocompromised children and adults. , 1986, Pediatrics.

[10]  A J Davison,et al.  The complete DNA sequence of varicella-zoster virus. , 1986, The Journal of general virology.

[11]  K. Yamanishi,et al.  Long-term protective immunity of recipients of the OKA strain of live varicella vaccine. , 1985, Pediatrics.

[12]  P. Keller,et al.  Three major glycoprotein genes of varicella-zoster virus whose products have neutralization epitopes , 1984, Journal of virology.

[13]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[14]  A. Kingsman,et al.  Production and Purification of Hybrid Ty-VLPs. , 1992, Methods in molecular biology.

[15]  C. Grose Glycoproteins encoded by varicella-zoster virus: biosynthesis, phosphorylation, and intracellular trafficking. , 1990, Annual review of microbiology.

[16]  M. Levin,et al.  Phenotype, cytotoxic, and helper functions of T cells from varicella zoster virus stimulated cultures of human lymphocytes. , 1989, Viral immunology.

[17]  A. Hinman,et al.  A benefit-cost analysis of a childhood varicella vaccination programme. , 1985, Postgraduate medical journal.